|
|
|
EKR
THERAPEUTICS EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF INDUSTRY
VETERAN TONY SCULLION EKR Therapeutics, Inc. a privately held specialty pharmaceutical company specializing in oncology supportive care products announced today the election of Tony Scullion as a member of its Board of Directors. “Tony Scullion brings to our board over 30 years of experience in the healthcare industry,” said Howard Weisman, EKR’s Chairman and Chief Executive Officer. “His broad strategic, operational and business development experience and high level relationships within the pharmaceutical and biotechnology industry will serve EKR well as we expand our business. Our ability to recruit someone of Tony’s stature to our team is a strong endorsement of the EKR business model and value proposition.” Mr. Scullion was Head of Global Business Development at GlaxoWellcome plc and served on the Management Committee of that company. At GlaxoWellcome, Mr. Scullion was responsible for corporate in-licensing, out-licensing and alliances with divisional functions based in the United States and the United Kingdom. Prior to joining GlaxoWellcome, he spent 16 years with Pfizer Inc, where he held senior marketing, strategic and operational positions with assignments in the United Kingdom, Asia and the U.S. headquarters. Mr. Scullion is currently Managing Director, Investment Banking at Leerink Swann & Co. and previously served as C.E.O. and Chairman of Memory Pharmaceuticals Corp. taking the company public in 2004 (Nasdaq :MEMY). “I am delighted to join the board of EKR and look forward to contributing to the growth of EKR’s business. EKR has a unique position in the market as a specialty pharmaceutical company entirely focused on supportive cancer care. EKR’s focus on helping patients optimize their quality of life throughout their primary cancer treatment is timely and necessary.” Mr. Scullion said. Mr. Scullion holds a B.Sc. in physiology and a M.Sc. in pharmacology from the University of London and is a Member of the Chartered Institute of Marketing. He is also Chairman of the Board of Trellis Bioscience and served previously on the boards of Memory Pharmaceuticals, Dynogen Pharmaceuticals and the Biotechnology Council of New Jersey (BCNJ). About EKR Therapeutics, Inc. EKR Therapeutics (www.ekrtx.com) was founded to provide prescription products and therapeutic solutions that support and improve the quality of life of cancer patients. As new and increasingly effective therapies emerge, more patients survive cancer. Oncology supportive care is becoming an increasingly critical component in support of patients as they progress through the complex arena of oncology treatment. The management team of EKR believes that cancer survival is largely impacted by the appropriate management of side effects encountered by patients undergoing therapy. EKR Therapeutics is committed to collaborating with the full scope of healthcare practitioners in helping patients adhere to primary treatment through the use of supportive care products.
|
|
|
